UnknownPhase 2NCT04397497

Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ospedale San Raffaele
Principal Investigator
Lorenzo Dagna, MD
Ospedale San Raffaele
Intervention
Mavrilimumab(drug)
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20202020

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04397497 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials